Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Multinational, Randomized, Double-blind, Parallel-group, 16-week Placebo-controlled Study With a 36-Week Extension to Investigate the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis Despite Treatment With Topical Medications (The HILLIER Study)

NCT04605094 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT04605094
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04605094 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Multinational, Randomized, Double-blind, Parallel-group, 16-week Placebo-controlled Study With a 36-Week Extension to Investigate the Use of Benralizumab for Patients With Moderate to Severe Atopic Dermatitis Despite Treatment With Topical Medications (The HILLIER Study)
Lead sponsor
AstraZeneca
Phase
Phase 2
Overall status
Terminated
Start date
November 12, 2020
Completion date
September 13, 2022
Enrollment
194 (actual)
Sites
51

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis